The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.

Br J Cancer · 2013 · PMC3738117 · PMID 23868011

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The model showed a strong trend for interaction between BMI and treatment regarding DFS (0.07) although this did not reach statistical significance.

also in 111,027 other papers

a strong trendno p-value reported

The significantly decreased risk of disease recurrence in normal weight patients treated with additional 3 years of anastrozole translated into a strong trend for a better OS compared with normal weight patients without further treatment.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.